Phase I Clinical Study of the Dietary Supplement, <i>Agaricus blazei</i> Murill, in Cancer Patients in Remission

<table>The opposite reaction of <i>Agaricus  blazei</i> Murill derivatives. Our study of safety clinical trail showed that food allergy and digestive discomfort, associated with <i>Agaricus  blazei</i> Murill product, were noted as new findings.</table>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Phase I Clinical Study of the Dietary Supplement, <i>Agaricus blazei</i> Murill, in Cancer Patients in Remission 

Evidence-Based Complementary and Alternative Medicine

Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission

Figure 2